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Case Report
Two Cases of Corneal Ulcer due to Methicillin-Resistant 
Staphylococcus aureus in High Risk Groups
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Considering the popular use of antibiotic-containing eyedrops in Korea, it is important to know the emerging anti-
biotic-resistant strains of bacteria before treating infectious eye diseases. This is especially important in high-risk 
groups because of the high incidence of resistant infections and the subsequent treatment requirements. We report 
two cases of methicillin-resistant Staphylococcus aureus (MRSA) corneal ulcers in high-risk groups. The first case 
involved a patient who had keratitis after using antibiotic- and steroid-containing eyedrops to treat a corneal opacity 
that developed after repeated penetrating keratoplasty. The second case involved a patient who used anti-
biotic-containing eyedrops and a topical lubricant on a regular basis for >1 month to treat exposure keratitis due to 
lagophthalmos. The second patient’s problems, which included a persistent superficial infiltration, developed after 
brain tumor surgery. Both cases showed MRSA on corneal culture, and the corneal ulcers improved in both patients 
after the application of vancomycin-containing eyedrops. In conclusion, MRSA infection should be considered in 
corneal ulcers that have a round shape, mild superficial infiltration, and slow progression, especially in high-risk 
groups. This report includes descriptions of the characteristic features, antibiotic sensitivities, prevention, and suc-
cessful treatment with vancomycin-containing eyedrops for MRSA corneal ulcers. 
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Subsequent to the development of penicillin G in 1942, 
Staphylococcus aureus infections responded well to treatment 
[1]. After Kirby [2]
 identified the first penicillin-resistant 
Staphylococcus aureus in 1994, problems with resistant 
strains have increased. After the 1960s, methicillin showed 
resistance to the penicillinase that was spotlighted as a lead-
ing factor in resistance [3]. Unfortunately, as a result of the 
popular use of methicillin, methicillin-resistant Staphylococcus 
aureus (MRSA) was first reported in 1961 [4,5]. Since the 
late 1970s, MRSA has become a prominent infection in the 
hospital, especially in intensive care units (ICUs). In fact, 
some studies have reported that MRSA accounts for 40% to 
70% of ICU staphylococcal infections [6,7]. 
Although MRSA does not often infect healthy individuals, 
it does often infect compromised hosts, including long-term 
inpatients, immunosuppressed patients, and patients who use 
antibiotics for a long time [8]. Individuals with MRSA in-
fections are refractory to most treatments and are difficult to 
properly treat [9]. In 1991, Insler et al. [10] reported that fluo-
roquinolones were effective for treating MRSA infections. 
Based on that study, fluoroquinolones were selected as the 
first-line treatment for bacterial keratitis, and the FDA also 
approved them as a treatment for bacterial keratitis. In 1992 
Snyder and Katz [11] reported ciprofloxacin-resistant bacte-
rial corneal ulcers, and following that report, ciprofloxacin- 
resistant strains have frequently been found worldwide.
MRSA often effects high-risk patients, is easily transmitted, 
and acts as the source for infections in a variety of anatomic 
areas. Once a MRSA infection occurs, treatment can be diffi-
cult due to delayed treatment and co-existing diseases, espe-
cially in high-risk groups. Although there have been 3 case 
reports of MRSA ocular infections since 2002 in Korea, we 
describe two cases of MRSA-corneal ulcers in high-risk pa-
tients, and consider the characteristic features and methods 
by which to prevent future MRSA ocular infections.KM Lee, et al. MRSA Infections in High Risk Groups
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Fig. 1. Corneal ulcer after penetrating keratoplasty and persistent 
use of levofloxacin and steroid eyedrops (case 1). On slit lamp ex-
amination, a 4×3 mm round corneal opacity with a corneal epi-
thelial defect associated with mild superficial stromal infiltration 
was found at the 2 to 3 o/c area around the penetrating keratoplasty 
stitch. Corneal edema was also noted.
Fig. 2. Recovery of the corneal ulcer after 2 months of vancomycin 
eyedrops (case 1). The corneal epithelial defect with infiltration dis-
appeared, but the corneal opacity remained. The corneal edema 
resolved. 
Case Report
Case 1
A 47-year-old female presented to our institution with di-
minished vision on the left side and red eye for 2 months. Her 
past history was not significant, except for partial penetrating 
keratoplasty of the left eye 18 months prior to treat a corneal 
ulcer. She experienced one episode of graft rejection 12 
months prior to presentation, and since then had been using 
eyedrops containing levofloxacin (Cravit; Taejoon Pharm, 
Seoul, Korea) and 1% rimexolone (Vexol; Alcon Laby Inc., 
Forth Worth, TX, USA) 4 times a day. After the rejection, a 
2×2 mm, round-shaped corneal haziness associated with 
mild superficial infiltration had been present at the suture site 
in the 2 o/c area. We thought that this was a suture-related in-
fection, so we removed the suture 6 months prior to presentation. 
After removal of the suture, the corneal haziness improved. 
In order to prevent additional rejection, we recommended the 
use of eyedrops containing levofloxacin and 1% rimexolone, 
and artificial tears 4 times a day. 
When the patient visited us with the above symptoms, eyelid 
examination revealed a greasy appearance and meibomian 
gland plugs that were determined to be posterior blepharitis 
on the left upper and lower eyelids. On slit lamp examination, 
a 4×3 mm, round-shaped corneal haziness and epithelial de-
fect associated with mild superficial stromal infiltration was 
found at the junction between the graft and donor site at the 2 
to 3 o/c area. The cornea was edematous and the thickness 
was 761 μm (Fig. 1). The corneal ulcer had progressed slow-
ly and seemed to be chronic, so we performed a corneal gram 
stain and culture. 
We recommended warm massage and scrubbing of the up-
per lid and prescribed a lid cleanser (Blephasol; Samil 
Pharm, Seoul, Korea) in an effort to improve the eyelid 
hygiene. We also recommended use of eyedrops containing 
5% moxifloxacin (a 4th generation fluoroquinolone) every 2 
hours and 0.15% amphotericin 4 times a day, because we 
were unsure whether the infection was fungal or bacterial. 
We also recommended reducing the use of Vexol, a steroid 
eyedrop she had been using, to once a day. There was no im-
provement after 4 weeks with this treatment. Eventually, the 
corneal culture grew MRSA (ofloxacin resistance was also 
shown). According to the antibiotic sensitivity testing, we 
prescribed fortified 2.5% vancomycin-containing eyedrops 6 
times a day. After 4 weeks, the corneal ulcer decreased to 2×3 
mm in size, and we recommended reducing the use of the 
2.5% vancomycin-containing eyedrops to 4 times a day. 
After 8 weeks, the corneal epithelium was healed completely 
and the corneal thickness returned to normal (581 μm) (Fig. 2).
Case 2
A 62-year-old man presented with red eye, ocular pain, and 
eyewax on his right eye. He had a history of brain surgery to 
treat a brain tumor 1 year prior to presentation. After the sur-
gery, a right-sided facial nerve palsy was noted, which re-
duced his blinking reflex. Postoperative exposure keratitis 
developed, and he began to use eyedrops containing oflox-
acin (Ocuflox; Samil Pharm) and artificial tears 4 times a 
day. 
On examination of the eyelids, a greasy appearance and 
meibomian gland plugs, which resembled thick toothpaste 
upon compressing the upper lid, were found, and posterior 
blepharitis involving the right upper and lower eyelids was 
diagnosed. On slit lamp examination, mild ciliary injection 
at the conjunctiva, an 8×8 mm round-shaped corneal hazi-
ness and epithelial defect associated with mild superficial 
stromal infiltration, and a 1.5 mm high anterior chamber hy-
popyon were found (Fig. 3). Gram stain and culture of the Korean J Ophthalmol Vol.24, No.4, 2010
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Fig. 4. (A) Gram stain of the eye discharge showed gram-positive spherical, paired bacteria. (B) The agar plate culture of the eye discharge 
showed large yellow colonies which were Staphylococcus aureus and small white colonies which were Staphylococcus epidermidis (case 2).
Fig. 3. Corneal ulcer after persistent use of levofloxacin eyedrops 
and lubricant for exposure keratitis (case 2). On slit lamp examina-
tion, an 8×8 mm round corneal ulcer with superficial stromal in-
filtration was found. The anterior chamber contained a 1.5 mm hy-
popyon associated with ciliary injection. 
Fig. 5. Recovery of the corneal ulcer after 5 days of vancomycin 
eyedrops (case 2). The corneal ulcer decreased in size to 5×4 mm. 
The superficial infiltration and hypopyon also decreased in size. 
corneal tissue were performed. We recommended warm 
massage and scrubbing the upper lid with a lid cleanser 
(Blephasol) in order to improve the eyelid hygiene. We also 
recommended the use of eyedrops containing 5% moxi-
floxacin every 2 hours, alternating with 5% ceftazidime (a 
3rd generation cephalosporin) every 2 hours. Additionally, 
we prescribed oral antibiotics. There was no improvement 
in the corneal ulcer or the hypopyon after 4 days of 
treatment. After this, as we believed the ulcer was neuro-
trophic and we decided to reduce the frequency of eyedrops 
to 6 times a day. However, after 3 days, there was no 
improvement. MRSA was eventually detected in the initial 
corneal culture, which took 1 week to grow (resistance to 
ofloxacin was also shown) (Fig. 4). Based on the antibiotic 
sensitivity testing, we prescribed fortified 2.5% vancomycin- 
containing eyedrops 6 times a day. After 5 days, the corneal 
ulcer size, superficial stromal infiltration, and hypopyon all 
decreased (Fig. 5). We then recommended a reduction in the 
use of the eyedrops containing 2.5% vancomycin to 4 times 
a day. By the 2 week follow-up visit, the corneal epithelium 
had healed completely.
Discussion 
The prevalence of MRSA differs depending on the group 
which is being studied; for example, the prevalence of 
MRSA was reported to be 0.1% in Geneva’s Hospital [12], 
2.8% in a San Francisco nosocomial community in 2000 
[13], and 6.8% in a homeless group in San Francisco in 2003 
[14]. The prevalence of MRSA infection is quite different 
among societies, but it is almost universally increasing. 
MRSA infections have many different appearances in differ-
ent sites, and also show multiple resistances to antibiotics 
making treatment quite difficult. Infections in immunocom-
promised patients can cause severe life-threatening prob-
lems, such as necrotizing cellulitis, pneumonia, and sepsis KM Lee, et al. MRSA Infections in High Risk Groups
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[15]. In hospital infections, MRSA can be transmitted from 
patient-to-patient, via clinical materials, physician’s hands, 
and hospital instruments. This makes preventing the spread 
of MRSA almost impossible [1,15-20]. Ocular MRSA in-
fections manifest as blepharitis, conjunctivitis, keratitis, da-
cryocystitis, endophthalmitis, and orbital cellulitis. Generally, 
MRSA ocular conditions do not respond to commercially- 
used eyedrops, which can cause a delay in treatment and can 
lead to severe complications, including permanent loss of vi-
sion [21-26]. 
According to the study by Sotozono et al. [8], ocular MRSA 
infections can be divided into 4 steps. The first step is the 
asymptomatic carrier state or the patient who shows only 
conjunctivitis. The second step is the patient who shows a 
corneal epithelial defect with superficial infiltration. The 
third step is the patient who shows superficial keratitis with a 
corneal ulcer which progresses slowly and causes corneal 
stromal infiltration. The fourth step is the patient who shows 
corneal perforation due to severe keratitis. Thus, MRSA cor-
neal ulcers have many manifestations, and can be treated 
with vancomycin-containing eyedrops or ointment according 
to each step, while intravenous vancomycin can be used in 
severe cases [8]. 
According to Kato and Hayasaka [27], MRSA exists as 
normal flora in the conjunctiva in 1.3% of the population. 
High-risk factors for ocular MRSA infection are known to be 
previous long-term use of antibiotic-containing eyedrops, 
long-term use of steroids, long-term hospitalization, systemic 
disease (respiratory failure, diabetes, cancer, and hepatic fail-
ure), ocular immunocompromised states (dry eyes, ocular 
surface diseases, and Stevens-Johnson syndrome), long-term 
use of contact lenses, and previous ocular surgery (partial 
penetrating keratoplasty and refractive surgery) [15,25]. 
Patients who have had a keratoplasty, as in case 1, have mul-
tiple risk factors. Not only do they have a history of previous 
ocular surgery, but they also likely have a history of 
long-term use of antibiotic- and steroid-containing eyedrops 
to prevent rejection and infection. Donor rejection must be 
excluded when corneal irritation symptoms develop, and 
consequently proper treatment can be delayed. The clinical 
findings of the cornea in rejection are quite different when 
compared to bacterial keratitis, including round superficial 
stromal infiltration and chronicity. Fungal keratitis should 
also be considered. In these situations, the use of steroid or 
antifungal eyedrops can aggravate the corneal ulcer and 
cause corneal toxicity, which can lead to severe complica-
tions, including corneal perforation. Therefore, if a patient 
has a slowly progressive chronic corneal ulcer and has risk 
factors for a MRSA infection, they should be examined and a 
MRSA corneal ulcer should be suspected. Corneal culture 
and antibiotic sensitivity testing must be performed to estab-
lish the exact diagnosis. 
In patients who have been hospitalized for a long time, as 
in case 2, it is important to consider that MRSA could be a 
nosocomial infection. Nosocomial MRSA infections can 
cause worsening of underlying diseases, and the prevention 
of nosocomial MRSA spread is becoming increasingly 
important. Most transmission of MRSA in hospital inpatients 
is thought to be via transiently-colonized healthcare workers 
[28,29]. Environmental contamination is also a source of 
MRSA spread. Boyce et al. [30] found that 73% of hospital 
rooms with patients infected with MRSA and 69% of rooms 
w i t h  p a t i e n t s  c o l o n i z e d  w i t h  M R S A  h a v e  s o m e  e n v i r o n -
mental contamination. In the same study, nurses con-
taminated their gloves 42% of the time in rooms with MRSA 
patients despite only touching environmental contamination. 
Other potential environmental reservoirs include computer 
keyboards used by clinicians [31], blood pressure cuffs, 
showers, and bathtubs [32]. Dietze et al. [33] found that 
MRSA can survive on the external surfaces of sterile goods 
packaged for over 38 weeks. Therefore, hand hygiene may be 
the single most important measure for controlling trans-
mission of MRSA. For that reason, in MRSA patients con-
firmed by bacterial culture and antibiotic sensitivity testing, 
isolation and sterilization of the patient’s medical materials 
and handwashing by healthcare workers are of the utmost im-
portance [34]. The medical staff must have a thorough under-
standing of such policies.
Although MRSA keratoconjunctivitis can be treated with 
vancomycin-containing eyedrops or ointments, MRSA in-
fections are of great concern to ophthalmologists because 
these ocular infections, including blepharitis, conjunctivitis, 
keratitis, or endophthalmitis, respond poorly to conventional 
antibiotic treatments and are sometimes sight-threatening. 
Vancomycin-containing eyedrops have several problems, 
including not yet being manufactured commercially. 
Consequently they have to be prepared directly in the hospital, 
which means they can be easily contaminated, may have high 
toxicity to the corneal epithelium, and may have unstable 
acidity which makes long-term storage difficult. Additionally, 
vancomycin-containing eyedrops might not be familiar to all 
ophthalmologists [35]. Unfortunately, with the high rate that 
bacteria are now developing antibiotic resistance, we expect 
that vancomycin resistant Staphylococcus will also become a 
problem. We should therefore choose antibiotics carefully 
using the results of bacterial culture and antibiotic sensitivity 
testing. 
In corneal ulcers with a round-shaped, mild superficial in-
filtration that have a slow progression and in lesions that do 
not improve with β-lactam antibiotics, MRSA infection 
should be considered, especially in high-risk groups. These 
high-risk groups include patients who have had penetrating 
keratoplasty and exposure keratitis. In such cases, bacterial 
culture and antibiotic sensitivity testing must be performed 
and treatment decisions should be based on the results of 
these tests. Also, healthcare workers should practice serial 
hand washing and careful isolation of medical materials from 
known MRSA patients in order to prevent transmission of 
MRSA. The prevalence and transmission of MRSA in the 
community are increasing and preventing MRSA infection is Korean J Ophthalmol Vol.24, No.4, 2010
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becoming an increasingly important consideration. 
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